Cargando…
The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system was originally discovered in prokaryotes and functions as part of the adaptive immune system. The experimental research of many scholars, as well as scientific and technological advanceme...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493308/ https://www.ncbi.nlm.nih.gov/pubmed/34605326 http://dx.doi.org/10.1177/15330338211045206 |
_version_ | 1784579096171249664 |
---|---|
author | Lv, Wei Li, Tao Wang, Shanshan Wang, Huihui Li, Xuemei Zhang, Shubing Wang, Lianzi Xu, Yuanhong Wei, Wei |
author_facet | Lv, Wei Li, Tao Wang, Shanshan Wang, Huihui Li, Xuemei Zhang, Shubing Wang, Lianzi Xu, Yuanhong Wei, Wei |
author_sort | Lv, Wei |
collection | PubMed |
description | The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system was originally discovered in prokaryotes and functions as part of the adaptive immune system. The experimental research of many scholars, as well as scientific and technological advancements, has allowed prokaryote-derived CRISPR/Cas genome-editing systems to transform our ability to manipulate, detect, image, and annotate specific DNA and RNA sequences in the living cells of diverse species. Through modern genetic engineering editing technology and high-throughput gene sequencing, we can edit and splice covalently closed circular DNA to silence it, and correct the mutation and deletion of liver cancer genes to achieve precise in situ repair of defective genes and prohibit viral infection or replication. Such manipulations do not destroy the structure of the entire genome and facilitate the cure of diseases. In this review, we discussed the possibility that CRISPR/Cas could be used as a treatment for patients with liver cancer caused by hepatitis B virus infection, and reviewed the challenges incurred by this effective gene-editing technology. |
format | Online Article Text |
id | pubmed-8493308 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-84933082021-10-07 The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer Lv, Wei Li, Tao Wang, Shanshan Wang, Huihui Li, Xuemei Zhang, Shubing Wang, Lianzi Xu, Yuanhong Wei, Wei Technol Cancer Res Treat Review The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system was originally discovered in prokaryotes and functions as part of the adaptive immune system. The experimental research of many scholars, as well as scientific and technological advancements, has allowed prokaryote-derived CRISPR/Cas genome-editing systems to transform our ability to manipulate, detect, image, and annotate specific DNA and RNA sequences in the living cells of diverse species. Through modern genetic engineering editing technology and high-throughput gene sequencing, we can edit and splice covalently closed circular DNA to silence it, and correct the mutation and deletion of liver cancer genes to achieve precise in situ repair of defective genes and prohibit viral infection or replication. Such manipulations do not destroy the structure of the entire genome and facilitate the cure of diseases. In this review, we discussed the possibility that CRISPR/Cas could be used as a treatment for patients with liver cancer caused by hepatitis B virus infection, and reviewed the challenges incurred by this effective gene-editing technology. SAGE Publications 2021-10-04 /pmc/articles/PMC8493308/ /pubmed/34605326 http://dx.doi.org/10.1177/15330338211045206 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Lv, Wei Li, Tao Wang, Shanshan Wang, Huihui Li, Xuemei Zhang, Shubing Wang, Lianzi Xu, Yuanhong Wei, Wei The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer |
title | The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer |
title_full | The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer |
title_fullStr | The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer |
title_full_unstemmed | The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer |
title_short | The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer |
title_sort | application of the crispr/cas9 system in the treatment of hepatitis b liver cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493308/ https://www.ncbi.nlm.nih.gov/pubmed/34605326 http://dx.doi.org/10.1177/15330338211045206 |
work_keys_str_mv | AT lvwei theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT litao theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT wangshanshan theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT wanghuihui theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT lixuemei theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT zhangshubing theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT wanglianzi theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT xuyuanhong theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT weiwei theapplicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT lvwei applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT litao applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT wangshanshan applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT wanghuihui applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT lixuemei applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT zhangshubing applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT wanglianzi applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT xuyuanhong applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer AT weiwei applicationofthecrisprcas9systeminthetreatmentofhepatitisblivercancer |